Novogen Ltd., of Sydney, said it engaged contract research organization Novotech for an upcoming phase I study of Cantrixil, a cyclodextrin-based drug containing the active ingredient TRXE-002-1, in patients with refractory/recurrent peritoneal malignancies with malignant ascites, including ovarian cancer.